A patient with a mesenchymal tumor and hypophosphatemic osteomalacia was studied before and after tumor excision. Initial laboratory values included normal serum calcium, decreased serum phosphorus and tubular reabsorption of phosphate, undetectable 1,25-dihydroxyvitamin D, and normal parathyroid hormone. Histomorphometry of a bone biopsy specimen showed evidence of increased osteoclastic bone resorption. By 16 hours after tumor removal, 1,25-dihydroxyvitamin D level had normalized, but serum phosphorus level was unchanged; at 28 hours, both serum phosphorus value and tubular reabsorption of phosphate were within normal limits. It is concluded that tumor removal is associated with rapid correction both of 1,25-dihydroxyvitamin D production and of renal phosphate wasting. Increased bone resorption suggests the production of an osteoclast activator by the tumor and may explain the typically normal serum calcium value in this disorder.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0002-9343(87)90075-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Facile synthesis of plasmonic BP@Au nanomatrix for sensitive detection of irinotecan and its active SN-38 metabolite via laser desorption/ionization mass spectrometry.
Mikrochim Acta
January 2025
Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou, 215123, Jiangsu, China.
A new methodology is presented for the rapid, specific, and sensitive detection of irinotecan (CPT-11), a chemotherapeutic agent utilized in the treatment of cancer, along with its metabolically active derivative, SN-38, via laser desorption/ionization mass spectrometry (LDI MS). The method includes the detection of camptothecin (CPT), which can be utilized as an internal standard for the quantitative assessment of both CPT-11 and SN-38 in mouse serum. The approach utilizes a plasmonic two-dimensional (2D) black phosphorus nanosheet (BPN)-gold nanomatrix (BP@Au) in LDI MS.
View Article and Find Full Text PDFThe role of vitamin D in slipped capital femoral epiphysis in children and adolescents: a retrospective case-control study.
Front Endocrinol (Lausanne)
January 2025
Department of Pediatric Orthopaedics, ShengJing Hospital of China Medical University, Shenyang, China.
Objective: To explore the correlation between vitamin D levels, related endocrine/metabolic factors, and the risk of slipped capital femoral epiphysis (SCFE) in children and adolescents, and to assess whether vitamin D levels are associated with SCFE severity.
Methods: A retrospective case-control study was conducted from March 2014 to October 2023 in Shengjing hospital. Patients diagnosed with SCFE were categorized as the SCFE group.
Cross Sectional Study of Vitamin D Levels in Western Rajasthan and Meta-Analysis for Estimation of Vitamin D Levels.
Indian J Clin Biochem
January 2025
Department of Orthopedics, All India Institute of Medical Sciences, Jodhpur, India.
Many studies showed Vitamin D deficiency is highly prevalent in healthy individuals. We planned to study the normal levels of Vitamin D in healthy individuals and make recommendation for defining deficiency of 25(OH)D in Indian population. ormal healthy subjects 18 to 60 years of age were included.
View Article and Find Full Text PDFA machine learning-based model for predicting the risk of cognitive frailty in elderly patients on maintenance hemodialysis.
Sci Rep
January 2025
School of Nursing, Chengdu Medical College, Chengdu, China.
Elderly patients undergoing maintenance hemodialysis (MHD) face a heightened risk of cognitive frailty (CF), which significantly compromises quality of life. Early identification of at-risk individuals and timely intervention are essential. Nevertheless, current CF risk prediction models fall short in accuracy to adequately fulfill clinical requirements.
View Article and Find Full Text PDFTenapanor: A novel therapeutic agent for dialysis patients with hyperphosphatemia.
Ther Apher Dial
January 2025
Division of Nephrology, Endocrinology, and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Patients on dialysis often develop hyperphosphatemia, contributing to an increased risk of cardiovascular events and mortality. Currently, several types of phosphate binders (PBs) exist for the treatment of hyperphosphatemia, but they are sometimes associated with drug-specific side effects and high pill burden, making it difficult to control serum phosphorus appropriately. Tenapanor, which has a novel mechanism to reduce serum phosphorus via selective sodium/proton exchange transporter 3 inhibition, was approved for hyperphosphatemia in Japan in 2023.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!